Background: It has been proposed that asthma control may be achieved in part by minimizing airway inflammation. The simultaneous effects of inhaled steroids associated with long-acting b-agonists and leukotriene antagonists on pulmonary function and airway inflammation are still largely unexplored in children with moderate persistent asthma. Objectives: The aim of this study was to investigate the effects of add-on therapy with long-acting b-agonists and leukotriene antagonists on FEV 1 and exhaled nitric oxide levels (FE NO ) in children. Methods: Forty-eight steroid-naïve atopic asthmatic children, 7-11 years of age, were randomly treated in four groups for two consecutive one-month periods, as follows: (1) first month: budesonide 200 mg twice daily; second month: budesonide 400 mg twice daily;
Introduction
The evidence that asthma is a chronic inflammatory disease of the airways supports the regular use of an antiinflammatory treatment, even in patients with mild persistent disease. 1 Currently, inhaled corticosteroids (ICS) represent the most effective anti-inflammatory treatment for the majority of asthmatic patients with persistent asthma. 1 Nevertheless, potential side effects of long-term treatment with high daily dosages have to be considered, particularly in children. Based on this issue, the most recent revisions of international guidelines for asthma management suggest an add-on therapy with either long-acting b 2agonists (LABAs) or leukotriene antagonists (LTRAs) as an alternative to an increased dose of ICS in adults and children with moderate persistent asthma. 1 However, LABAs and LTRAs are characterized by markedly different pharmacologic properties that could provoke substantially different effects on the basic mechanisms of the disease, 2,3 which are largely unexplored in children. 4 Exhaled nitric oxide (FE NO ) is considered a valid parameter for a non-invasive monitoring of airway inflammation [5] [6] [7] [8] and it has been shown to be a useful marker for assessment of pharmacologic therapy for airway inflammation. 9 Recently, it was shown that measurements of FE NO levels may be used to guide treatment of asthma. 10 The aim of this study was to investigate whether the different treatment options proposed by international guidelines for children with moderate asthma are comparable in controlling the disease, not only in terms of improving lung function but also improving airway inflammation, as measured by FE NO levels.
Methods

Subjects
Fifty-one steroid-naïve atopic asthmatic children (27 girls and 24 boys), from 7 to 11 years of age, attending the Pediatric Department of Second University of Naples (Italy), were screened in this study. All patients were sensitized to house dust mites and met the criteria for the American Thoracic Society definition of asthma. 11 All children demonstrated an increase of at least 12% in forced expiratory volume in 1 s (FEV 1 ) after administration of 200 mg of salbutamol and were classified as moderate, persistent asthmatics. 1, 11 A medical history was collected and children underwent a physical examination, spirometry with reversibility to b 2 -agonists, FE NO measurement, and skin prick test to the most common allergens. Three children were unable to comply with one or more tests; therefore, 48 children were admitted to the study. The study was performed out of season for seasonal allergens to avoid the confounding effect of such exposure. Patients had not received oral or ICS, LABAs, or LTRAs for at least 4 weeks before admission to the study; the only treatment used during that period was inhaled salbutamol. Children also did not use b 2 -agonists within the 24-h period before lung capacity measurements.
The protocol had the ethical approval by the second University of Naples, and all subjects signed informed consent.
Study design
This was a double-blind study in which 48 patients were randomly allocated into one of four parallel groups of 12 patients each for two consecutive one-month periods, as follows: (1) first month: budesonide (BD) 200 mg twice daily; second month: budesonide 400 mg twice daily (BD 400/BD 800 group); (2) first month: budesonide 200 mg twice daily+formoterol (FM) 9 mg twice daily; second month: budesonide 200 mg twice daily+montelukast (MK) 5 mg once daily (BD 400+FM/BD 400+MK group); (3) first month: budesonide 200 mg twice daily+montelukast 5 mg once daily; second month budesonide 200 mg+formoterol 9 mg twice daily (BD 400+MK/BD 400+FM group); (4) first and second month: budesonide 400 mg twice daily (BD 800/BD 800 group). Since this was a spontaneous study with no support of pharmaceutical industry and without official placebos or study-dedicated preparations, in order to keep the patients and the clinical investigators blind about the regimen of treatment, the following procedures were undertaken. Budesonide and formoterol Turbuhaler dedicated to the study were prepared by a doctor not involved in the clinical part of the study. The devices were unlabelled, those dedicated to placebo formoterol were carefully emptied and the reservoirs cleaned by suctioning with a vacuum pump. A non-matching placebo for montelukast was obtained by preparing a dedicated small sweet cherrytasting candy with a very similar shape, colour and taste of the active drug. Furthermore, the patients had never experienced before neither budesonide/formoterol nor montelukast treatment and therefore were unable to distinguish between active drug or placebo. An external doctor (not participating to the evaluation of the patients) prepared the study drugs and placebos, as well as the randomization table. The parents received sealed packages containing the study drugs, i.e. budesonide at one of the above referred concentrations and either the combination of active formoterol plus placebo montelukast or placebo formoterol plus active montelukast. The sealed packages were delivered when the patients had left the hospital and they had returned the used drugs to the doctor who prepared the packages, in order to keep the clinical investigators blind about the treatment regimen for each patient. A treatment randomization list was kept in a sealed envelope in order to know the allocation of every patient in the case of emergency.
Patients visited the clinic three times: immediately before initiation of treatment, at the end of the Month 1, and at the end of Month 2. At each visit, FE NO and spirometric measurements were performed.
Nitric oxide measurement
FE NO was measured with a chemiluminescence analyzer (Model 280 Nitric Oxide Analyzer, Severs Instrument Inc., Boulder, CO); the detection limit of the apparatus was 1-5 parts per billion (ppb), as required by ATS guidelines, with a ARTICLE IN PRESS resolution of 1 ppb. The analyzer was calibrated daily, using a certified NO mixture. Exhaled NO was recorded with the singlebreath method according to published guidelines. 12 Children inhaled to total lung capacity from NO-free air and exhaled a single breath (without nose clip) through a mouthpiece at a mouth pressure of 45 cm water and at an expiratory flow of 50 mL/s. Mouth pressure was displayed on a computer screen as a prompt for the children to maintain a steady flow. The measurement was rejected if a stable flow was not maintained for at least 6 s of exhalation. Nitric oxide was measured at the plateau and expressed in ppb.
Lung function and reversibility test
Following FE NO measurements, lung function variables forced vital capacity (FVC) and FEV 1 were measured using a dry spirometer (Vmax series 22; Sensormedics) according to published guidelines. 13 The best value of three measurements was recorded and expressed as a percentage of the predicted value. The reversibility test requires an increase of more than 12% in FEV 1 compared with baseline 15 min after inhalation of 200 mg salbutamol delivered by metered dose inhaler.
Statistical analysis
Results for FE NO and FEV 1 are reported as means7standard errors of the mean. Analysis of variance (ANOVA) was used to compare FE NO and spirometric values between and within groups. Significance was declared when Po0:05.
Results
There were no significant differences in mean baseline FE NO and FEV 1 among the four treatment groups (Tables 1 and 2) .
BD 400/BD 800 group: After one month of treatment with budesonide twice daily at 200 mg, mean FE NO decreased from 39.970.8-28.370.9 ppb ðPo0:01Þ (Fig. 1B) . At the end of Month 2 (twice-daily treatment with 400 mg budesonide), FE NO was 25.571.1 ppb. The change is FE NO from the end of Month 1 to the end of Month 2 was not significant. Mean FEV 1 increased from 76.2%72.5% of predicted at baseline to 84.1%72.4% at the end of Month 1 and to 86.7%72.4% at the end of Month 2 (Fig. 1A) . The increase from baseline to the end of Month 2 was significant ðPo0:05Þ.
BD 400+FM/BD 400+MK group: Mean FE NO decreased from 38.071.1 ppb at baseline to 24.870.9 ppb at the end of Month 1 ðPo0:01Þ for children treated with budesonide 200 mg+formoterol 9 mg twice daily (Fig. 1B) . After switching to budesonide 400 mg twice daily+montelukast 5 mg once daily, mean FE NO further decreased to 18.271.1 ppb ðPo0:01Þ at the end of Month 2. Mean FEV 1 increased from 75.3%71.7% of predicted at baseline to 94.2%73.4% at the end of Month 1 ðPo0:05Þ and further increased to 95.7%73.7% at the end of Month 2 (Fig. 1A) . The increase from baseline to the end of Month 2 was significant ðPo0:01Þ.
BD 400+MK/BD 400+FM group: FE NO mean values decreased significantly from 38.771.3 ppb at baseline to 19.071.1 ppb ðPo0:01Þ at the end of Month 1 (budesoni-de+montelukast), whereas it increased to 25.271.1 ppb ðPo0:05Þ at the end of Month 2 after 1 month of treatment with budesonide+formoterol ( Fig. 1B ). Mean FEV 1 increased from 77.0%72.2% of predicted to 95.7%73.0% at the end of Month 1 ðPo0:05Þ and to 97.0%71.6% at the end of Month 2 (Fig. 1A) . The increase from baseline to the end of Month 2 was significant ðPo0:01Þ.
BD 800/BD 800 group: After one month of therapy with budesonide 400 mg twice daily, mean FE NO decreased from 41.171.3 ppb to 27.171.3 ppb ðPo0:01Þ (Fig. 1B) . Little change was noted after the second month of treatment with budesonide 400 mg (27.771.4 ppb). The change from baseline to the end of Month 2 was significant ðPo0:01Þ. At the end of one month, mean FEV 1 increased from 79.0%71.6% of predicted to 86.0%71.6% (Fig. 1A) . At the end of Month 2, mean FEV 1 had increased to 89.071.6%. The increase from baseline to the end of Month 2 was significant ðPo0:05Þ.
Between-group comparisons: Mean FE NO was significantly lower after one month of treatment for children who had received budesonide+montelukast (BD 400+MK/BD 400+FM group) versus all other groups ðPo0:001Þ. Mean FEV 1 for this treatment regimen also was significantly higher at the end of one month of treatment compared with the value for the BD 400/BD 800 group treated twice daily with budesonide 200 mg. At the end of Month 2, the BD 400+FM/BD 400+MK group treated with budesonide+montelukast had a significantly greater decrease in FE NO than did the other groups ðPo0:001Þ. No significant difference was observed for FEV 1 among treatment groups at this evaluation time.
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Discussion
The present study demonstrated how the addition of montelukast to low dose (200 mcg bid) budesonide is able to induce an adjunctive effect on FE NO reduction as compared to both higher dosage (400 mcg bid) of budesonide and add-on therapy of formoterol to low dose budesonide.
Previous studies comparing the effect of LABAs with LTRAs in asthmatic patients not controlled by ICS alone determined a better effect with the addiction of LABA. [14] [15] [16] Nevertheless, a recent study in a large population of patients uncontrolled by ICS alone reported a better response to rescue medication and control of exercise-induced symptoms with montelukast than with salmeterol. 17 A recent meta-analysis of results up to the beginning of 2004 concluded that, in asthmatic adults for whom an add-on treatment to low-dose ICS was required, LABAs were superior to LTRAs in preventing asthma exacerbations, improving lung function, symptoms, and reducing in the use of rescue medications. 18 Most of the available comparative studies, including those considered in the metaanalysis, 18 are based on lung function or symptom reports. However, previous reports have demonstrated that these LABAs and LTRAs are characterized by substantially different effects on FE NO . 2, 3 In fact, whereas LABAs have been shown to have no effect on FE NO in children with mild asthma, 19 montelukast was able to reduce FE NO when it was used either as a monotherapy 20 or added to ICS. 21 More recently, Buchvald et al. 22 have compared the effects of salmeterol versus montelukast add-on therapy on FE NO in asthmatic children undergoing regular maintenance treatment with a daily dose of 400 mcg of budesonide. Studies show that levels of FE NO were higher after the addition of salmeterol, as compared with either placebo or montelukast. 22 Several reports have emphasized the importance of assessing airway inflammation in designing appropriate therapeutic strategies for asthma control. Green et al. 23 showed that a greater reduction in asthma exacerbation was achieved by minimizing eosinophilic airway inflammation rather than by following standard care. Measurement of FE NO levels has been proposed as a practical guide to treating asthma. 24 In the present study, if we consider the changes in FE NO with those observed for FEV 1 in the two groups with add-on therapy we might speculate that these parameters are differently influenced by the therapeutic strategies. In fact, FE NO and FEV 1 , improved significantly for two groups treated with add-on therapy (groups B and C) in the first period of treatment. In the second phase of the study, instead only the changes in FE NO , but not in FEV 1 reflect the switching effect from the therapeutic options. The FEV 1 changes observed after the first month only in the groups treated with either formoterol or montelukast confirm that in montelukast has a positive effect on lung function in children as recently demonstrated by two studies by Straub. 22, 23 The data from the present study regarding FEV 1 variations during treatment are partially in contrast with those presented by Buchvald et al. 22 In fact, in that study, the group treated with LABA was the only one with significant increase in FEV 1 , whereas the present data suggest that both formoterol and montelukast were able to induce an increase in FEV 1 at T1. However, when comparing the two studies in terms of lung function, the main difference is represented by the baseline level of FEV 1 , being 101% of predicted in children participating to Buchvald's study 22 (treated with 400 mcg/d maintenance dose of inhaled budesonide at the time of admission) in contrast to levels below 80% of predicted value in children participating to the present study (who did not receive inhaled steroids until one month before enrolment). The higher baseline levels in FEV 1 , with little room for improvement, may, therefore, contribute to explain the lack of effect on lung function for the group treated with montelukast in the study by Buchwald. 22 Similarly, the different therapeutic regimens may in part explain the different changes in FE NO levels observed in the two studies. In fact, in the present study, the FE NO levels at baseline were 110   100   90   80   70  0  T0  T1  T2   Time  FEV1 % of predicted   50  45  40  35  30  25  20  15  0  T0  T1 not influenced by previous treatment with ICS and, therefore, it was possible to show more evident changes during the study periods, with no floor effect.
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Since FE NO , but not FEV 1 , can reflect airway inflammation, an overall evaluation of the changes in the investigated parameters during this study allow to speculate that add-on therapy with montelukast, but not formoterol, is able to exert an adjunctive anti-inflammatory effect to low and medium dose budesonide in asthmatic children. In addition, the results of this study show that no difference in the investigated parameters could be observed between the two dosages of budesonide, therefore inducing to support the choice of an add-on therapy rather than an increase in the daily regimen of inhaled steroid in children not well controlled with low doses of budesonide.
In conclusion, this study has demonstrated that add-on therapy with montelukast to low dosage of budesonide is more effective than the addition of LABA or doubling the dose of budesonide in controlling airway inflammation measured as FE NO in asthmatic children.
